Skip to Content

Ibritumomab Dosage

Applies to the following strengths: 3.2 mg/2 mL

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for non-Hodgkin's Lymphoma

Day 7, 8, or 9 following initial rituximab infusion:
-Within 4 hours of rituximab, administer Y-90 ibritumomab 0.4 mCi/kg (14.8 MBq/kg) actual body weight intravenously over 10 minutes for patients with normal platelet count (Platelet count greater than 150,000/mm3).

Maximum dose: 32 mCi (1184 MBq) Y-90 ibritumomab dose regardless of actual body weight.

-Do not treat if platelets less than 100,000/mm3
-Initiate the regimen following recovery of platelet counts to at least 150,000/mm3 at least 6 weeks, but not more than 12 weeks, following the last dose of first-line chemotherapy

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Platelet count between 100,000/mm3 and 149,000/mm3 (in relapsed or refractory patients): Y-90 ibritumomab 0.3 mCi/kg (11.1 MBq/kg) actual body weight intravenously over 10 minutes


Consult WARNINGS section for dosing related precautions.


Data not available

Other Comments

Administration advice:
-Administer Y-90 ibritumomab through a free-flowing intravenous line.
-Use a 0.22 micron low-protein-binding in-line filter between the syringe and the infusion port.
-After injection, flush the line with at least 10 mL normal saline.

Storage requirements:
-Store the kit at 2C to 8C (36F to 46F). Do not freeze.

Reconstitution/preparation techniques:
-For information about the preparation of ibritumomab, see the manufacturer's product information.

-Monitor for extravasation during the injection